文献速递新发突发、热带与寄生虫病

PfSPZ疫苗在马里疟疾暴露成人中的安全性和保护效力:一项随机双盲1期试验

Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
PubMed 文献 · Lancet Infect Dis · 2017-02-16

该随机双盲安慰剂对照1期试验在马里疟疾暴露成人中评估PfSPZ疫苗的安全性和保护效力。疫苗组与安慰剂组不良事件无显著差异,仅见轻度局部或全身不良事件。

要点

  • PfSPZ疫苗在疟疾暴露成人中耐受良好,未观察到显著安全性问题。
  • 疫苗组疟原虫感染率66%,显著低于安慰剂组的93%。

核心结论

  • PfSPZ疫苗在马里疟疾暴露成人中安全且耐受良好,并对自然获得的恶性疟原虫感染显示出显著保护作用。

研究设计与样本

  • 在试点安全性队列开放标签剂量递增研究后,于马里Donéguébougou及周边村庄开展随机双盲安慰剂对照试验。
  • 招募18-35岁健康成人,按村庄分层和区组随机化1:1分配,接受5剂2·7×10^5 PfSPZ或生理盐水(第0、28、56、84、140天)。
  • 主要结局为安全性和耐受性,评估局部和全身反应原性及不良事件。
  • 安全性分析纳入至少接受一剂研究产品的所有参与者(疫苗组46人,安慰剂组47人)。
  • 探索性效力分析仅纳入完成全部5剂接种的参与者(疫苗组41人,安慰剂组40人)。

主要发现

  • 疫苗组与安慰剂组局部或全身不良事件及实验室异常无显著差异,两组仅发生1级(轻度)局部或全身不良事件。
  • 最常见的 solicited 全身不良事件为头痛(疫苗组3人[7%] vs 安慰剂组4人[9%]),其次为疲劳(安慰剂组1人[2%])、发热(安慰剂组1人[2%])和肌痛(每组各1人[2%])。
  • 疫苗组41人中有27人(66%)发生恶性疟原虫感染,安慰剂组40人中有37人(93%)发生感染。
  • 时间-感染分析疫苗效力风险比为0·517(95%CI 0·313-0·856,log-rank p=0·01)。
  • 比例分析疫苗效力风险比为0·712(95%CI 0·528-0·918,p=0·006)。

临床怎么用

  • 该1期试验提示PfSPZ疫苗在疟疾暴露成人中具有良好的安全性和初步保护效力,支持进一步开展更大规模临床试验验证。

局限性

  • 本研究为1期试验,样本量较小,效力分析仅纳入完成全部5剂接种的参与者。
  • 研究仅在马里一个地区开展,结果外推至其他疟疾流行区需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive individuals. We aimed to assess the safety and protective efficacy of PfSPZ Vaccine against naturally acquired P falciparum in malaria-experienced adults in Mali. METHODS: After an open-label dose-escalation study in a pilot safety cohort, we did a double-blind, randomised, placebo-controlled trial based in Donéguébougou and surrounding villages in Mali. We recruited 18-35-year-old healthy adults who were randomly assigned (1:1) in a double-blind manner, with stratification by village and block randomisation, to receive either five doses of 2·7 × 105 PfSPZ or normal saline at days 0, 28, 56, 84, and 140 during the dry season (January to July inclusive). Participants and investigators were masked to group assignments, which were unmasked at the final study visit, 6 months after receipt of the last vaccination. Participants received combined artemether and lumefantrine (four tablets, each containing 20 mg artemether and 120 mg lumefantrine, given twice per day over 3 days for a total of six doses) to eliminate P falciparum before the first and last vaccinations. We collected blood smears every 2 weeks and during any illness for 24 weeks after the fifth vaccination. The primary outcome was the safety and tolerability of the vaccine, assessed as local and systemic reactogenicity and adverse events. The sample size was calculated for the exploratory efficacy endpoint of time to first P falciparum infection beginning 28 days after the fifth vaccination. The safety analysis included all participants who received at least one dose of investigational product, whereas the efficacy analyses included only participants who received all five vaccinations. This trial is registered at ClinicalTrials.gov, number NCT01988636. FINDINGS: Between Jan 18 and Feb 24, 2014, we enrolled 93 participants into the main study cohort with 46 participants assigned PfSPZ Vaccine and 47 assigned placebo, all of whom were evaluable for safety. We detected no significant differences in local or systemic adverse events or laboratory abnormalities between the PfSPZ Vaccine and placebo groups, and only grade 1 (mild) local or systemic adverse events occurred in both groups. The most common solicited systemic adverse event in the vaccine and placebo groups was headache (three [7%] people in the vaccine group vs four [9%] in the placebo group) followed by fatigue (one [2%] person in the placebo group), fever (one [2%] person in the placebo group), and myalgia (one [2%] person in each group). The exploratory efficacy analysis included 41 participants from the vaccine group and 40 from the placebo group. Of these participants, 37 (93%) from the placebo group and 27 (66%) from the vaccine group developed P falciparum infection. The hazard ratio for vaccine efficacy was 0·517 (95% CI 0·313-0·856) by time-to-infection analysis (log-rank p=0·01), and 0·712 (0·528-0·918) by proportional analysis (p=0·006). INTERPRETATION: PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria season. FUNDING: US National Institutes of Health Intramural Research Program, Sanaria.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sissoko MS, Healy SA, Katile A, et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017. PMID: 28216244. doi:10.1016/S1473-3099(17)30104-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。